- Nextleaf Solutions has locked in a wholesale distribution agreement with Lineage Distribution in Manitoba
- The agreement will strengthen the company’s position and market presence in Manitoba as well as the northern territories
- Under the agreement, Lineage will distribute Nextleaf Solution’s complete product catalogue
- Shares of Nextleaf Solutions are up 21.05 per cent to C$0.11 as of 12:24 pm ET
Nextleaf Solutions (CSE:OILS) has locked in a wholesale distribution agreement with Lineage Distribution in Manitoba, which will see the distribution of the company’s complete product catalogue.
In a news release, the Vancouver-based biotech firm and licensed cannabis producer stated that its products will be distributed to more than 35 stock-keeping units (SKUs) across four categories including CBD and THC vapes; drops and oils; infused pre-rolls; and softgels.
The agreement will see the company’s products distributed across Manibota, the Northwest Territories, Nunavut and the Yukon.
“We are excited to debut our brands in the northern territories and bolster our presence in Manitoba through our partnership with Lineage, driving investor value and market expansion,” Emma Andrews, interim CEO of Nextleaf Solutions, said in a statement. “Delivering in-market support through a dedicated and reputable local partner will help drive sales growth and enhance awareness for our extensive lineup of new products slated for release this spring.”
Products released in spring 2024 will include those in the preroll category under the company’s Glacial Gold and High Plains brands.
Nextleaf Solutions develops a range of multi-patented, highly automated, closed-loop extraction and distillation technology that sets the global standard for processing cannabis at-scale.
The company currently manufactures more than 80 different products, across four categories for white label clients and house brands.
Shares of Nextleaf Solutions are up 21.05 per cent to C$0.11 as of 12:24 pm ET.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.